A Phase 3 Study of I-Metaiodobenzylguanidine or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)

Brief description of study

?The primary purpose of the study is to assess the effectiveness and safety of targeted radiopharmaceutical therapy with 131I-MIBG or crizotinib for patients with high-risk neuroblastoma. We want to know if the treatment can eliminate chemotherapy in patients likely cured with surgery alone and reduce toxicity for those need to undergo chemotherapy.

Clinical Study Identifier: s18-01766
ClinicalTrials.gov Identifier: NCT03067181
Principal Investigator: Chana Glasser.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.